Recently, another elegant and comprehensive study provided independent confirmation that therapeutic approaches based on TGFβ inhibition in breast cancer were most likely to be successful in patients with high grade, ER-negative disease of the claudin-low and basal subtypes (202). Here, TGFB1 is linked to breast carcinoma.